Herb Drug Interaction of Traditional Chinese Herb and Commonly Used Drugs
NCT ID: NCT00923000
Last Updated: 2009-06-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
50 participants
INTERVENTIONAL
2008-12-31
2009-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effects of Jing Si Herbal Tea on Physical and Psychological Symptoms in Peripheral Blood Hematopoietic Stem Cell Donors
NCT06141902
The Influence of Chinese Medicine on Metabolomics in Menopausal or Postpartum Women
NCT01264068
The Effectiveness of Chinese Medicine Nuan-gong-ye on Primary Dysmenorrhea
NCT06295822
Investigation on the Epidemic Prevention Effect of Using Chinese Medicine During the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Outbreak.
NCT05236309
the Effect of Chinese Herbs to Treat Thyroid Diseases With Different Iodine Intake
NCT01873014
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nubian with Long dan xie gan tang 3g
Nubian with Long dan xie gan tang
Nalbuphine 10mg with Long dan xie gan tang 3g with oral administration
Nalbuphine
Nalbuphine
Nalbuphine 10mg with oral administration
Morphine
Morphine
Morphine 10mg with oral administration
Morphine with Long dan xie gan tang
Morphine with Long dan xie gan tang
Morphine 10mg with oral administration
Nubian with Long dan xie gan tang 3g tid
Nalbuphine with Long dan xie gan tang
Nalbuphine 10mg with Long dan xie gan tang 3g tid with oral administration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nalbuphine
Nalbuphine 10mg with oral administration
Morphine
Morphine 10mg with oral administration
Morphine with Long dan xie gan tang
Morphine 10mg with oral administration
Nalbuphine with Long dan xie gan tang
Nalbuphine 10mg with Long dan xie gan tang 3g tid with oral administration
Nubian with Long dan xie gan tang
Nalbuphine 10mg with Long dan xie gan tang 3g with oral administration
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body weight within 80-120% of ideal body weight
* Acceptable medical history, physical examination and clinical laboratory determinations
Exclusion Criteria
* Donating greater than 150 ml of blood within two months prior to Period I
* Taking any prescription medication or any nonprescription medication within 14 days prior to Period I doing
* Receiving any investigational drug within 30 days prior to Period I dosing
* Taking any drug known to induce or inhibit hepatic drug metabolism within 30 days prior to the beginning of the study
* Any clinically significant diseases
* History of allergic response to nalbuphine or related drugs and traditional Chinese herbs
20 Years
40 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tri-Service General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tri-Service General Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hung-Tai Ho
Role: PRINCIPAL_INVESTIGATOR
Tri-Service General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tri-Service General Hospital
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Shung-Tai Ho, Professor
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TSGHIRB096-02-015-A
Identifier Type: -
Identifier Source: secondary_id
DDI-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.